The only second-line drug, obeticholic acid (Ocaliva), approved by the Food and Drug Administration in 2016, a potent farnesoid X receptor (FXR) agonist, has been shown to cause treatment-associated pruritus and hepatotoxicity (5, 6, 7, 8). This evidence concerns the gene NR1H4 and Pruritus.